Lung Shunt Reduction for Yttrium-90 Radioembolization: Chemoembolization Versus Radioembolization

xlomafota13 shared this article with you from Inoreader Lung Shunt Reduction for Yttrium-90 Radioembolization: Chemoembolization <em>Versus</em> Radioembolization Via In vivo (Athens, Greece) In Vivo. 2021 Jul-Aug;35(4):2305-2312. doi: 10.21873/invivo.12504. ABSTRACT AIM: To evaluate the efficacy of chemoembolization versus radioembolization in reducing lung shunt fraction (LSF) in patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: In this retrospective study, from March 2012 to January 2021, 457 patients with HCC underwent planning angiography and 99mTc-macroaggregated albumin imaging for possible yttrium-90 radioembolization. Ten patients underwent radioembolization, and seven patients underwent conventional chemoembolization for LSF reduction, and a second 99mTc-macroaggregated albumin imaging was obtained approximately 1 month later. LSF under both procedures was compared with the Mann-Whitney U-test and the Wilcoxon signed-rank test. RESULTS: In the radioembolization group, the mean first and second LSF were 13.0±6.9% and 20.9±9.6%, respectively (p=0.059); after radi oembolization, LSF was lower in three patients but higher in seven patients. In the chemoembolization group, the mean first and second LSF were 26.1±17.3% and 8.7±5.5%, respectively (p=0.018); after chemoembolization, LSF was reduced in all seven patients. CONCLUSION: Chemoembolization appears to be more effective in reducing LSF within 1 month compared with radioembolization. PMID:34182510 | DOI:10.21873/invivo.12504 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.